University of Free State: Clinical trial on Ivermectin for COVID-19

Organisation: Position: Deadline Date: Location:

FARMOVS, a wholly owned clinical research company of the University of the Free State (UFS), together with several medical and scientific experts at the university, is currently in the process of preparing a clinical trial protocol to determine the efficacy of Ivermectin for COVID-19 in a randomised, controlled study according to the requirements of the legal professions, in order to submit it for approval to the relevant national regulatory authority.

FARMOVS is a South African specialty full-service clinical research organisation conducting ICH-GCP-compliant Phase I to IV clinical trials. FARMOVS’ competitive advantage is its wealth of bioequivalence and Phase I experience and expertise, patient recruitment success, and a clinical research facility with the only onsite ISO (International Organisation for Standardisation) and GLP (Good Laboratory Practice) certified bioanalytical laboratory on the African continent.

By participating in the preparation of the clinical trial protocol, FARMOVS and the UFS remain supportive of and committed to contributing to the development of treatments and treatment strategies to battle the COVID-19 pandemic. Should the clinical trial protocol be approved by the relevant national regulatory authority, the UFS will be the first university in South Africa to attempt such a study.

The university management is aware of a WhatsApp voice clip being circulated, in which reference is made to a particular meeting, and mention is made of the role the institution is playing in establishing the efficacy of Ivermectin for COVID-19. The voice clip is premature and was shared with a small group, from where it went viral. The voice clip is also not factual – specifically regarding the university and its alleged opinion pertaining to the usage and need for scientific investigation into the matter.

The UFS is committed to rigorous science and evidence-based research, and both FARMOVS and the university fully support the published opinions and guidelines of the South African Health Products Regulatory Authority (SAHPRA) and the scientific advisory boards established by the scientific community, as well as the stance of the South African government on ivermectin for COVID-19.

Issued by the University of the Free State


Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.